中牧股份(600195.SH):子公司獲得新獸藥註冊證書
格隆匯5月12日丨中牧股份(600195.SH)公佈,根據《獸藥管理條例》和《獸藥註冊辦法》規定,農業農村部審查批准公司的子公司湖北中牧安達藥業有限公司、中牧南京動物藥業有限公司,分別與其他單位聯合申報的兩個產品為新獸藥,核發《新獸藥註冊證書》。新獸藥產品基本情況如下:
(一)加米黴素
1.通用名稱:加米黴素;2.研製單位:保定冀中生物科技有限公司、山東魯抗舍裏樂藥業有限公司、青島農業大學、河北天象生物藥業有限公司、保定冀中藥業有限公司、保定九孚生化有限公司、湖北中牧安達藥業有限公司。3.類別:二類;4.新獸藥註冊證書號:(2020)新獸藥證字12號;5.監測期:4年。
(二)加米黴素注射液
1.通用名稱:加米黴素注射液;2.研製單位:保定冀中生物科技有限公司、上海公誼藥業有限公司、廣東温氏大華農生物科技有限公司動物保健品廠、山東魯抗舍裏樂藥業有限公司高新區分公司、青島農業大學、東北農業大學、中國農業大學、保定九孚生化有限公司、中牧南京動物藥業有限公司、保定冀中藥業有限公司、湖北迴盛生物科技有限公司。3.類別:二類;4.新獸藥註冊證書號:(2020)新獸藥證字13號;5.監測期:4年;6.主要成分:加米黴素;7.用途:用於治療對加米黴素敏感的胸膜肺炎放線桿菌、多殺巴氏桿菌和副豬嗜血桿菌引起的豬呼吸道疾病。8.用法與用量:按加米黴素計。肌內注射:一次量,豬每1kg體重6mg(相當於每25kg體重注射1ml)。僅用一次。每個注射部位的給藥體積不超過5ml。9.規格:50ml∶7.5g。
加米黴素是大環內酯類動物專用抗生素,抗菌譜廣、抗菌活性強,具有吸收迅速、起效快,殘留低、安全性高等特點。此次獲得新獸藥註冊證書將對豐富公司化藥產品序列,提升市場競爭力產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.